Suppr超能文献

PLGA-5-氟尿嘧啶缓释微球的药代动力学研究与效果评价。

Pharmacokinetic study and effectiveness evaluation of slow-release PLGA-5-fluorouracil microsphere.

机构信息

General Surgery Department, The 309th Hospital of the PLA, No A17, Heishanhu road, Haidian district, Beijing 100091, China.

出版信息

Cancer Chemother Pharmacol. 2013 Feb;71(2):351-9. doi: 10.1007/s00280-012-2016-6. Epub 2012 Nov 8.

Abstract

PURPOSE

The aim was to develop a slow-release poly-lactic-co-glycolic acid (PLGA)-5-fluorouracil microsphere, study the pharmacokinetic characteristics as well as to evaluate the effectiveness and safety of this preparation on colorectal tumor in vivo.

METHODS

The PLGA-5-fluorouracil microsphere was prepared based on a spray-drying method, and the drug loading of 5-fluorouracil (the percentage of 5-fluorouracil content in the whole microsphere), in vitro 5-fluorouracil release profile and pharmacokinetic characteristics were carried out through high-performance liquid chromatography. The inhibiting effect on tumor growth and safety was examined using in vivo subcutaneously (s.c.) inoculated colorectal tumor models of nude mice.

RESULTS

The size of the microsphere was less than 100 μm, drug loading was 20 % and drug release time lasted as long as 30 days. Slow-release PLGA-5-fluorouracil microsphere had longer half-life time (t (1/2)), larger apparent volume of distribution (V ( d )) and smaller area under the curve (AUC) compared with 5-fluorouracil. PLGA-5-fluorouracil microsphere significantly restrained tumor growth and this effect correlated with decreased expression of vascular endothelial growth factor in tumor cells. Body weight measurement and blood analysis did not suggest significant adverse effects on the mice during the study.

CONCLUSIONS

The slow-release PLGA-5-fluorouracil microsphere developed here was suitable for regional use; it has pharmacokinetic advantages and appears safe and effective in controlling the tumor growth. This preparation shows promise in reducing local recurrence of colorectal cancer after resection, but needs further investigation.

摘要

目的

研制一种聚乳酸-羟基乙酸共聚物(PLGA)-5-氟尿嘧啶缓释微球,研究其药代动力学特征,并评价其在体内对结直肠肿瘤的疗效和安全性。

方法

采用喷雾干燥法制备 PLGA-5-氟尿嘧啶微球,采用高效液相色谱法测定载药量(5-氟尿嘧啶占微球总重量的百分比)、体外 5-氟尿嘧啶释放曲线和药代动力学特征。采用裸鼠皮下接种结直肠肿瘤模型,观察其对肿瘤生长的抑制作用及安全性。

结果

微球粒径小于 100μm,载药量为 20%,药物释放时间长达 30 天。与 5-氟尿嘧啶相比,缓释 PLGA-5-氟尿嘧啶微球具有更长的半衰期(t(1/2))、更大的表观分布容积(V(d))和更小的曲线下面积(AUC)。PLGA-5-氟尿嘧啶微球能显著抑制肿瘤生长,其作用与肿瘤细胞血管内皮生长因子表达下调有关。在研究过程中,体重测量和血液分析均未提示对小鼠有明显的不良反应。

结论

本研究制备的 PLGA-5-氟尿嘧啶缓释微球适合局部应用,具有药代动力学优势,在控制肿瘤生长方面安全有效。该制剂有望降低结直肠癌切除术后的局部复发率,但需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验